What is Zacks Research’s Estimate for BMRN Q3 Earnings?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Equities researchers at Zacks Research raised their Q3 2025 earnings estimates for BioMarin Pharmaceutical in a report issued on Monday, February 17th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will earn $0.73 per share for the quarter, up from their previous estimate of $0.72. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical’s FY2025 earnings at $2.71 EPS, Q2 2026 earnings at $0.86 EPS, Q3 2026 earnings at $0.91 EPS, Q4 2026 earnings at $0.97 EPS and FY2026 earnings at $3.52 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 10.10%. The company had revenue of $747.31 million for the quarter, compared to analysts’ expectations of $711.05 million.

A number of other analysts have also recently commented on BMRN. Wedbush reaffirmed an “outperform” rating and set a $94.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday. StockNews.com raised shares of BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Wolfe Research initiated coverage on shares of BioMarin Pharmaceutical in a research report on Friday, November 15th. They set an “outperform” rating and a $95.00 price target on the stock. Scotiabank upped their price target on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the company a “sector perform” rating in a research report on Thursday. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $70.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday. Seven equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $93.81.

BioMarin Pharmaceutical Stock Performance

Shares of BioMarin Pharmaceutical stock opened at $68.25 on Thursday. The company has a quick ratio of 2.62, a current ratio of 4.27 and a debt-to-equity ratio of 0.11. BioMarin Pharmaceutical has a twelve month low of $60.63 and a twelve month high of $94.85. The stock has a market cap of $13.01 billion, a price-to-earnings ratio of 31.02, a P/E/G ratio of 0.58 and a beta of 0.28. The company’s fifty day moving average is $64.84 and its 200 day moving average is $71.05.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. nVerses Capital LLC bought a new position in BioMarin Pharmaceutical in the 3rd quarter valued at $28,000. LRI Investments LLC grew its position in BioMarin Pharmaceutical by 856.9% in the fourth quarter. LRI Investments LLC now owns 488 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 437 shares in the last quarter. TD Private Client Wealth LLC grew its position in BioMarin Pharmaceutical by 57.4% in the third quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 186 shares in the last quarter. SBI Securities Co. Ltd. purchased a new position in BioMarin Pharmaceutical in the fourth quarter worth $36,000. Finally, CIBC Private Wealth Group LLC grew its position in BioMarin Pharmaceutical by 64.2% in the fourth quarter. CIBC Private Wealth Group LLC now owns 596 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 233 shares in the last quarter. 98.71% of the stock is owned by institutional investors.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.